Miscarriage, Recurrent
13
2
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
ANXA5 M2 Haplotyping in IVF Patients and Embryos
Unexplained Recurrent Pregnancy Loss: New Therapeutic Perspectives
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients
The Role of Hydrosalpinx in Recurrent Miscarriage
The Role of NLRP Gene Family (NLRP1~14) in Recurrent Miscarriage and Infertility
Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure
Sildenafil Citrate in Early Unexplained Recurrent Pregnancy Loss
Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score
The Effect of the Ovarian Reserve on the Recurrent Pregnancy Loss
Use of Cyclosporin A for the Treatment of Recurrent Miscarriage
Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
PAR Family Polymorphisms and Placental Invasion Disorders